Status:

UNKNOWN

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Lead Sponsor:

Kovach Eye Institute

Conditions:

Vitrectomy

Macular Pucker

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel

Detailed Description

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts, when placed within the lower eye lid canaliculus or both the upper and lower canaliculi for the treatment...

Eligibility Criteria

Inclusion

  • A patient's study eye must meet the following criteria to be eligible for inclusion in the study:
  • Symptomatic macular pucker with retinal edema
  • Age 18 years and older
  • Scheduled vitrectomy and internal limiting membrane peel
  • Willing and able to comply with clinic visits and study related procedures
  • Willing and able to sign the informed consent form

Exclusion

  • A patient who meets any of the following criteria will be excluded from the study:
  • Patients under the age of 18
  • Pregnancy ( must be ruled out in women of child-bearing age with pregnancy test)
  • Active infectious systemic disease
  • Active infectious ocular or extraocular disease
  • Obstructed nasolacrimal duct in the study eye (s)
  • Hypersensitivity to dexamethasone or prednisolone eye drops
  • Patients being treated with immunomodulating agents in the study eye(s)
  • Patient being treated with immunosuppressants and/or oral steroids
  • Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

Key Trial Info

Start Date :

April 27 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04501367

Start Date

April 27 2021

End Date

December 31 2024

Last Update

June 29 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kovach Eye Institute

Elmhurst, Illinois, United States, 60126